Kv1.3 in the spotlight for treating immune diseases

María Navarro-PérezJesusa CaperaAnna Benavente-GarciaSilvia CassinelliMagalí Colomer-MoleraAntonio Felipea Molecular Physiology Laboratory,Departament de Bioquímica i Biomedicina Molecular,Institut de Biomedicina (IBUB),Universitat de Barcelona,Barcelona,Spainb The Kennedy Institute of Rheumatology,Nuffield Department of Orthopaedics Rheumatology & Musculoskeletal Sciences,University of Oxford,Oxford,UK
DOI: https://doi.org/10.1080/14728222.2024.2315021
IF: 6.797
2024-02-09
Expert Opinion on Therapeutic Targets
Abstract:Introduction Kv1.3 is the main voltage-gated potassium channel of leukocytes from both the innate and adaptive immune systems. Channel function is required for common processes such as Ca 2+ signaling but also for cell-specific events. In this context, alterations in Kv1.3 are associated with multiple immune disorders. Excessive channel activity correlates with numerous autoimmune diseases, while reduced currents result in increased cancer prevalence and immunodeficiencies.
pharmacology & pharmacy
What problem does this paper attempt to address?